Search Results - "Liwacki, Susana"
-
1
Accumulative risk of clinical event in high-risk radiologically isolated syndrome in Argentina: data from the nationwide registry RelevarEM
Published in Journal of neurology (01-04-2022)“…Introduction We aimed to analyze the accumulative risk of MRI and OB factors for evolution from RIS to MS in subjects included in the Argentinean MS registry…”
Get full text
Journal Article -
2
The Argentinean multiple sclerosis registry (RelevarEM): Methodological aspects and directions
Published in Multiple sclerosis and related disorders (01-07-2019)“…•No ongoing nationwide registry exists in Latin America.•We describe the methodology behind RelevarEM, the first nationwide MS registry in Argentina and…”
Get full text
Journal Article -
3
Assessing attacks and treatment response rates among adult patients with NMOSD and MOGAD: Data from a nationwide registry in Argentina
Published in Multiple sclerosis journal - experimental, translational and clinical (01-07-2021)“…We aimed to examine treatment interventions implemented in patients experiencing neuromyelitis optica spectrum disorders (NMOSD) attacks (frequency, types, and…”
Get full text
Journal Article -
4
Mortality of neuromyelitis optica spectrum disorder patients in an Argentinean population: A study from the RelevarEM registry
Published in Multiple sclerosis journal - experimental, translational and clinical (01-10-2023)“…We aimed to evaluate mortality and causes of death among Argentinean neuromyelitis optica spectrum disorder (NMOSD) patients and identify predictors of death…”
Get full text
Journal Article -
5
Achieving no evidence of disease activity-3 in highly active multiple sclerosis patients treated with cladribine and monoclonal antibodies
Published in Multiple sclerosis journal - experimental, translational and clinical (01-01-2023)“…Background We aimed to determine the proportion of highly active multiple sclerosis patients under high-efficacy therapies (HETs) achieve no evidence of…”
Get full text
Journal Article -
6
Real-World Effectiveness and Safety of Cladribine in Multiple Sclerosis: Longitudinal Data From the Nationwide Registry in Argentina
Published in Clinical neuropharmacology (01-07-2024)“…The aim was to evaluate patient profiles, effectiveness and safety of cladribine (CLAD) in patients with relapsing-remitting multiple sclerosis in Argentina…”
Get full text
Journal Article -
7
Treatment strategies and responses for attacks of neuromyelitis optica spectrum disorder: A real-world retrospective cohort study
Published in Journal of the neurological sciences (15-07-2024)“…We aimed to assess the treatment strategies utilized in patients with neuromyelitis optica spectrum disorder (NMOSD) experiencing relapses, including their…”
Get full text
Journal Article -
8
Real-World Effectiveness and Safety of Cladribine in Multiple Sclerosis: Longitudinal Data From the Nationwide Registry in Argentina
Published in Clinical neuropharmacology (01-07-2024)“…The aim was to evaluate patient profiles, effectiveness and safety of cladribine (CLAD) in patients with relapsing-remitting multiple sclerosis in Argentina…”
Get full text
Journal Article -
9
Selection of disease modifying therapies in multiple sclerosis based on patient's age and disease activity: Data from a nationwide registry
Published in Journal of the neurological sciences (15-06-2024)“…Knowledge of the safety and efficacy of disease-modifying therapies (DMTs) in older patients with Multiple Sclerosis (pwMS) is limited due to their exclusion…”
Get full text
Journal Article -
10
Occurrence of area postrema syndrome during follow-up: phenotype and influence over NMOSD activity in LATAM in real-world settings
Published in Journal of neurology (01-07-2024)“…Introduction We aimed to assess the frequency, duration, and severity of area postrema syndrome (APS) during follow-up in neuromyelitis optica spectrum…”
Get full text
Journal Article -
11
Cladribine use trend in Latin America: the changes in patient profile impact in the drug effectiveness
Published in Neurological sciences (01-12-2024)“…Introduction Cladribine was approved for Multiple Sclerosis (MS) in our country in 2018. A previous study by our group showed that its use among high efficacy…”
Get full text
Journal Article -
12
Barriers to access and unmet needs to neuromyelitis optica spectrum disorders care in an Argentinean cohort
Published in Multiple sclerosis and related disorders (01-02-2023)“…•NMOSD is associated with increased health care utilization and with a significant financial burden.•100 NMOSD patients from Argentina were included and…”
Get full text
Journal Article -
13
Disease activity after discontinuation of disease-modifying therapies in patients with multiple sclerosis in Argentina: data from the nationwide registry RelevarEM
Published in Neurological research (New York) (01-02-2023)“…The discontinuation of disease-modifying therapies (DMTs) in multiple sclerosis (MS) is commonly seen in real-world settings due to several factors. The aim of…”
Get full text
Journal Article -
14
Disability outcomes in NMOSD and MOGAD patients: data from a nationwide registry in Argentina
Published in Neurological sciences (2023)“…The objective was to evaluate time to reach an EDSS of 4, 6, and 7 in NMOSD and MOGAD patients included in the Argentinean MS and NMOSD registry (RelevarEM,…”
Get full text
Journal Article -
15
Evaluation of the use of high-efficacy treatments (HETs) in patients with relapsing-remitting multiple sclerosis in Argentina
Published in Multiple sclerosis and related disorders (01-11-2023)“…•There are limited data regarding the use of high-efficacy treatments in LATAM.•One third of those patients received HETs as the first treatment, in second…”
Get full text
Journal Article -
16
Traditional first-line treatment failure rates in neuromyelitis optica spectrum disorder patients included in the Argentinean registry (RelevarEM)
Published in Multiple sclerosis and related disorders (01-09-2024)“…•We studied 139 NMOSD patients from Argentina on AZA (n = 105), MMF (n = 5), or RTX (n = 29).•The annualized relapse rate decreased post-treatment in 51.1 %,…”
Get full text
Journal Article -
17
Rebound activity after fingolimod cessation: A case – control study
Published in Multiple sclerosis and related disorders (01-01-2022)“…•The median time to rebound activity after fingolimod discontinuation was 50 days (IQR 37.25 – 86.75).•The main reason for stopping fingolimod in this cohort…”
Get full text
Journal Article -
18
Access and unmet needs to multiple sclerosis care in a cohort of Argentinean patients
Published in Multiple sclerosis and related disorders (01-08-2019)“…•MS has a high burden of disease, with a high impact on the healthcare system.•We surveyed 219 MS patients in 13 provinces from Argentina.•MS patients did not…”
Get full text
Journal Article -
19
What percentage of AQP4-ab-negative NMOSD patients are MOG-ab positive? A study from the Argentinean multiple sclerosis registry (RelevarEM)
Published in Multiple sclerosis and related disorders (01-04-2021)“…•RelevarEM is the first nationwide MS and NMOSD registry in Argentina•Patients with phenotype of suspected NMOSD were evaluated•165 patients (79 AQP4-ab…”
Get full text
Journal Article -
20
Incidence of COVID-19 after vaccination in people with multiple sclerosis in Argentina: Data from the nationwide registry RelevarEM
Published in Multiple sclerosis and related disorders (01-12-2022)“…•Incidence of COVID-19 after vaccination in MS patients in Argentina was evaluated.•Cohort study conducted between May 2021 and December 2021.•twenty COVID-19…”
Get full text
Journal Article